AOD-9604
Phase II TrialsAlso known as: Advanced Obesity Drug 9604, hGH Fragment 177-191
Educational Content Only
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The FDA has not evaluated many of the peptides discussed here. Always consult a licensed healthcare provider before making any health decisions.
AOD-9604 is a synthetic peptide fragment derived from the C-terminus of human growth hormone, studied in the context of fat metabolism and lipolysis regulation. Research has examined its potential role in stimulating lipolytic activity without the growth-promoting or insulin-desensitizing effects associated with full-length HGH. Animal models and early clinical studies have explored its metabolic profile.
The following areas have been examined in research contexts. This does not constitute medical advice or imply proven efficacy in humans.
- Fat Loss & Metabolism
- Anti-Aging & Longevity
Research suggests AOD-9604 may mimic the lipolytic region of HGH by activating beta-adrenergic receptors and stimulating fat oxidation pathways without binding to IGF-1 receptors or affecting blood glucose levels.
Has progressed through Phase II clinical trials with an acceptable safety profile reported. Not FDA-approved for human use. The FDA has classified it as a research chemical.
Selected peer-reviewed papers from research literature. These are educational references only and do not imply proven efficacy or safety in humans.
- The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β(3)-AR knock-out mice
Heffernan M et al. (2001). Endocrinology.
Want to learn more?
Ask Research Chat about AOD-9604Half-Life
~30 minutes
Administration
subcutaneous injection, oral (studied in trials)
Legal Status (US)
Research chemical in the US. Not FDA-approved. Investigated in Phase II trials for obesity.
197 indexed research passages
Related Peptides
GHRP-2 (pralmorelin) is a synthetic hexapeptide and potent growth hormone secretagogue studied for its ability to stimulate pulsatile GH release through the ghrelin receptor. It has been investigated in clinical studies and is sometimes used diagnostically for growth hormone deficiency assessment in some countries.
Hexarelin is a synthetic hexapeptide and potent growth hormone secretagogue studied for its ability to stimulate GH release and its potential cardioprotective effects in animal models and early human studies.
IGF-1 (insulin-like growth factor 1) is an endogenous polypeptide hormone critical for growth, development, and metabolic homeostasis. It is produced primarily in the liver in response to GH signaling and acts through IGF-1 receptors on virtually all tissues. Recombinant IGF-1 (mecasermin) is FDA-approved for children with severe primary IGF-1 deficiency.
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) consisting of the full 44-amino acid GHRH sequence with a trans-3-hexenoic acid modification to improve stability. It is FDA-approved for reduction of excess abdominal fat (lipodystrophy) in HIV-infected patients receiving antiretroviral therapy, and has been studied for cognitive function in aging.